tetano
Editor, Senior Moderator
Influenza Other Respir Viruses
. 2024 Jun;18(6):e13342.
doi: 10.1111/irv.13342. Late-Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022-April 2023
Jessie R Chung[SUP] 1 [/SUP], Philip Shirk[SUP] 1 [/SUP], Manjusha Gaglani[SUP] 2 3 [/SUP], Manohar B Mutnal[SUP] 2 3 [/SUP], Mary Patricia Nowalk[SUP] 4 [/SUP], Krissy Moehling Geffel[SUP] 4 [/SUP], Stacey L House[SUP] 5 [/SUP], Tara Curley[SUP] 5 [/SUP], Karen J Wernli[SUP] 6 7 [/SUP], Erika L Kiniry[SUP] 6 [/SUP], Emily T Martin[SUP] 8 [/SUP], Ivana A Vaughn[SUP] 9 [/SUP], Vel Murugan[SUP] 10 [/SUP], Efrem S Lim[SUP] 11 [/SUP], Elie Saade[SUP] 12 [/SUP], Kiran Faryar[SUP] 13 [/SUP], Olivia L Williams[SUP] 14 [/SUP], Emmanuel B Walter[SUP] 14 [/SUP], Ashley M Price[SUP] 1 [/SUP], John R Barnes[SUP] 1 [/SUP], Juliana DaSilva[SUP] 1 [/SUP], Rebecca Kondor[SUP] 1 [/SUP], Sascha Ellington[SUP] 1 [/SUP], Brendan Flannery[SUP] 1 [/SUP]
Affiliations
Background: The 2022-23 US influenza season peaked early in fall 2022.
Methods: Late-season influenza vaccine effectiveness (VE) against outpatient, laboratory-confirmed influenza was calculated among participants of the US Influenza VE Network using a test-negative design.
Results: Of 2561 participants enrolled from December 12, 2022 to April 30, 2023, 91 laboratory-confirmed influenza cases primarily had A(H1N1)pdm09 (6B.1A.5a.2a.1) or A(H3N2) (3C.2a1b.2a.2b). Overall, VE was 30% (95% confidence interval -9%, 54%); low late-season activity precluded estimation for most subgroups.
Conclusions: 2022-23 late-season outpatient influenza VE was not statistically significant. Genomic characterization may improve the identification of influenza viruses that circulate postinfluenza peak.
Keywords: influenza; vaccination; vaccine effectiveness.
. 2024 Jun;18(6):e13342.
doi: 10.1111/irv.13342. Late-Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022-April 2023
Jessie R Chung[SUP] 1 [/SUP], Philip Shirk[SUP] 1 [/SUP], Manjusha Gaglani[SUP] 2 3 [/SUP], Manohar B Mutnal[SUP] 2 3 [/SUP], Mary Patricia Nowalk[SUP] 4 [/SUP], Krissy Moehling Geffel[SUP] 4 [/SUP], Stacey L House[SUP] 5 [/SUP], Tara Curley[SUP] 5 [/SUP], Karen J Wernli[SUP] 6 7 [/SUP], Erika L Kiniry[SUP] 6 [/SUP], Emily T Martin[SUP] 8 [/SUP], Ivana A Vaughn[SUP] 9 [/SUP], Vel Murugan[SUP] 10 [/SUP], Efrem S Lim[SUP] 11 [/SUP], Elie Saade[SUP] 12 [/SUP], Kiran Faryar[SUP] 13 [/SUP], Olivia L Williams[SUP] 14 [/SUP], Emmanuel B Walter[SUP] 14 [/SUP], Ashley M Price[SUP] 1 [/SUP], John R Barnes[SUP] 1 [/SUP], Juliana DaSilva[SUP] 1 [/SUP], Rebecca Kondor[SUP] 1 [/SUP], Sascha Ellington[SUP] 1 [/SUP], Brendan Flannery[SUP] 1 [/SUP]
Affiliations
- PMID: 38923314
- PMCID: PMC11194453
- DOI: 10.1111/irv.13342
Background: The 2022-23 US influenza season peaked early in fall 2022.
Methods: Late-season influenza vaccine effectiveness (VE) against outpatient, laboratory-confirmed influenza was calculated among participants of the US Influenza VE Network using a test-negative design.
Results: Of 2561 participants enrolled from December 12, 2022 to April 30, 2023, 91 laboratory-confirmed influenza cases primarily had A(H1N1)pdm09 (6B.1A.5a.2a.1) or A(H3N2) (3C.2a1b.2a.2b). Overall, VE was 30% (95% confidence interval -9%, 54%); low late-season activity precluded estimation for most subgroups.
Conclusions: 2022-23 late-season outpatient influenza VE was not statistically significant. Genomic characterization may improve the identification of influenza viruses that circulate postinfluenza peak.
Keywords: influenza; vaccination; vaccine effectiveness.